Effect of chromium consumption in HIV patients with abnormal distribution of body fat

Not Applicable

• Conditions: HIV infections, HIV-Associated Lipodystrophy Syndrome; C02.782.815.616.400; C02.782.815.616.400.400

• Registration Number: RBR-26kgx5
• Lead Sponsor: Faculdade de Medicina de Ribeirão Preto USP

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2017-09-19
• Last Update Posted: 29 May 2023

Recruitment & Eligibility

• Status: Recruitment completed
• Sex: Male
• Target Recruitment: Not specified

Inclusion Criteria

Men; adult; HIV-positive; ART for at least 6 months; with lipodystrophy.

Exclusion Criteria

Previous thyroidectomy or thyroid dysfunction; in use of glucocorticoids at the last year; with signs or symptoms of opportunistic infections; hepatic dysfunction; renal dysfunction; using insulin or hypoglycemic; taking vitamin and or mineral supplementation.

Study & Design

• Study Type: Intervention
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Increased insulin sensitivity observed by HOMA-IR (Homeostatic Model Assessment - Insulin Resistance) from the observation of a variation of at least 5% in the pre and post intervention measurements.;Improvement of the lipid profile verified by total cholesterol, HDL-cholesterol, LDL-cholesterol and triglycerides of a variation of at least 5% in the pre and post intervention measurements.

Secondary Outcome Measures

Name	Time	Method
Reduction of pro-inflammatory biomarkers verified by TNF, IL-6, IL-8 and MCP-1; reduction of oxidative stress verified by malondiladeido (MDA) and glutathione (GSH) and<br>body composition verified by reduction of the body fat percentage of a variation of at least 5% in the pre and post intervention measurements.